Name change underscores the Company's transition to developing innovative targeted therapies in immunology, immuno-oncology, and rare genetic diseases Robust pipeline of six product candidates advancing in
August 6, 4:31 PM
Gainers Nuwellis (NASDAQ:NUWE) shares increased by 5.63% to $4.5 during Friday's after-market session. The market value of their outstanding shares is at $29.3 million.
Clinicaltrials.gov Site Shows Cerecor-Sponsored Study ‘A Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 in Adults With Complex Lymphatic Malformations’ Not Yet Recruiting
August 6, 8:55 AM
July 26, 5:03 PM
Gainers Cerecor (NASDAQ: CERC) shares are trading higher after the company announced initial Phase 1b results for CERC-002 in moderate to severe Crohn's Disease patients.
July 26, 4:32 PM
Gainers Eyegate Pharmaceuticals (NASDAQ:EYEG) stock increased by 25.64% to $3.92 during Monday's after-market session. The company's market cap stands at $27.8 million.
July 9, 5:20 PM
Gainers Delcath Systems (NASDAQ:DCTH) stock increased by 8.87% to $11.9 during Friday's after-market session. This security traded at a volume of 379 shares come close, making up 0.45% of its average volume over the last 100 days. The company's market cap stands at $87.4 million.
The Week Ahead In Biotech: Mediwound, Provention FDA Decisions, IPOs, Pending Clinical Readouts In Focus
June 27, 12:55 PM
Biotech stocks reversed course and closed the week ended June 25 higher, thanks to the positive broader market sentiment.
Cerecor Licenses Immune Checkpoint Program From Sanford Burnham Prebys Further Expanding Pipeline Of Immunology And Immuno-oncology Targets
June 23, 7:32 AM
Cerecor Inc. (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for immunology, immuno-oncology and rare genetic disorders, today announced that